Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4932798 | 1.00 | ROCK1 (1.00) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 | |
| SCHEMBL4936335 | 0.94 | ROCK1 (1.00) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 | |
| SCHEMBL4935013 | 0.91 | ROCK1 (1.00) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 | |
| SCHEMBL4937845 | 0.91 | ROCK1 (0.83) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 | |
| SCHEMBL4935272 | 0.90 | ROCK1 (1.00) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 | |
| SCHEMBL4935363 | 0.89 | ROCK1 (1.00) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 | |
| SCHEMBL4935665 | 0.86 | ROCK1 (0.76) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 | |
| SCHEMBL4933911 | 0.86 | ROCK1 (0.83) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 | |
| SCHEMBL4934586 | 0.85 | ROCK1 (0.74) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 | |
| SCHEMBL4933946 | 0.85 | ROCK1 (0.83) | ROCK1CYP3A4CYP2D6RPS6KB1RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | claimed |
| WO-2023223519-A1 | METHOD FOR DEACTIVATING ACTIVATED STELLATE CELLS | ＩＳＭ株式会社 | 2023-11-23 | — | — | WO | claimed |
| WO-2023199010-A1 | TREATMENT OF MUSCLE FIBROSIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2023-10-19 | — | — | WO | claimed |
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | disclosed |
| WO-2025094914-A1 | TRANSPLANTATION DEVICE CAPABLE OF ENCAPSULATING CELLS THEREIN AND USE THEREOF | 株式会社VC Cell Therapy | 2025-05-08 | — | — | WO | disclosed |
| US-20240400983-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-113490528-B | 3- (1-Oxo-5- (piperidin-4-yl) isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| WO-2024171957-A1 | TRANSPLANTATION OF PITUITARY HORMONE-PRODUCING CELLS | 国立大学法人東海国立大学機構 | 2024-08-22 | — | — | WO | disclosed |
| EP-4410962-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410963-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | Sumitomo Chemical Company, Limited (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-116731967-A | Method for preparing macrophage from multipotent stem cells by induced differentiation | 南京大学 | 2023-09-12 | — | — | CN | disclosed |
| EP-4214239-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS | University of Virginia Patent Foundation (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023054396-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | 住友化学株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023054395-A1 | CELL AGGREGATE INCLUDING PITUITARY HORMONE-PRODUCING CELLS AND METHOD FOR PRODUCING SAME | 住友ファーマ株式会社 | 2023-04-06 | — | — | WO | disclosed |
| EP-4117718-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2023277135-A1 | METHOD FOR PRODUCING CELLS CONSTITUTING NASAL EPITHELIUM, AND CELL POPULATION INCLUDING CELLS CONSTITUTING NASAL EPITHELIUM OR PROGENITOR CELLS THEREOF | 住友化学株式会社 | 2023-01-05 | — | — | WO | disclosed |
| WO-2022230977-A1 | CORD-LIKE AGGREGATES OF RETINAL PIGMENT EPITHELIAL CELLS, DEVICE AND PRODUCTION METHOD FOR PRODUCING SAME, AND THERAPEUTIC AGENT COMPRISING SAID CORD-LIKE AGGREGATES | 国立研究開発法人理化学研究所 | 2022-11-03 | — | — | WO | disclosed |
| WO-2022081869-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING DR5-INDUCED IMMUNE EVASION BY SOLID TUMORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | RHOA, MYLK2, MYLK | ROCK1 4/4885CYP3A4 4737/4885CYP2D6 4664/4885 |
| US-20230149295-A1 | INFLAMMATORY BOWEL DISEASE STEM CELLS, AGENTS WHICH TARGET IBD STEM CELLS, AND USES RELATED THERETO | EPCAM, FABP2, TPMT | ROCK1 2536/4885CYP3A4 3749/4885CYP2D6 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.